

toxicities that may be associated with a specific patient population. Numerous physiological changes can occur during disease conditions, and these changes can impact drug distribution, protein binding, clearance, drug metabolism, and tissue sensitivity. While we raise this question, we recognize that this point in and of itself can be the subject of an entire textbook. Nevertheless, it is a point worth considering as we use preclinical data to predict appropriate drug dosages in humans.

## REFERENCES

1. Li AP. Overview: hepatocytes and cryopreservation — a personal historical perspective. *Chemico-Biol Intervent* 1999; 121:1–5.
2. Nomeir AA, Markham P, Burka LT, Griffin RJ, Ghanayem BI. Species differences in the disposition and metabolism of nalidixic acid. *J Pharm Exp Therap* 1996; 279:222–230.
3. Lewis RW, Billington R, Debryune E, Gamber A, Lang B, Carpanini F. Recognition of adverse and nonadverse effects in toxicity studies. *Toxicol Pathol* 2002; 30:66–74.
4. Gad SC, Chengelis CP. *Acute Toxicology Testing*. 2d ed. San Diego: Academic Press, 1998.
5. Burger GT, Renne RA, Sagartz JW, Ayres PH, Coggins CRE, Mosberg AT, Hayes AW. Histological changes in the respiratory tract induced by inhalation of xenobiotics: physiologic adaptation or toxicity? *Toxicol Appl Pharmacol* 1989; 101:521–542.
6. Alcock SJ. An anti-inflammatory compound: non-toxic to animals, but with an adverse action in man. *Proc Eur Soc Stud Drug Toxicol* 1971; 12:184–190.
7. Barnes CD, Eltherington LG. *Drug Dosage in Laboratory Animals*. Berkeley and Los Angeles: University of California Press, 1965.
8. Ritschel WA, Siegel EG, Ring PE. Biopharmaceutical factors influencing LD50 Part I: viscosity. *Arzneim-Forsch (Drug Res)* 1974; 24:907–910.
9. Martinez M, Augsburg L, Johnston T, Jones WW. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations. *Adv Drug Deliv Rev* 2002; 54:805–824.
10. Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial CaCO<sub>2</sub> cell layers and everted gut sacs of rats. *Biochem Pharmacol* 2000; 59:665–672.
11. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. *Arch Biochem Biophys* 1995; 319:309–315.
12. Yamazaki T, Sato Y, Hanai M, Mochimaru J, Tsujino I, Sawada U, Horie T. Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx. *Cancer Lett* 2000; 149:153–161.
13. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I. Reversal of the multidrug resistance phenotype